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INTEGRATIVE REVIEW OF LITERATURE 
Análise de custos do transplante alogênico de células-tronco hematopoiéticas: uma revisão 
integrativa 
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integradora 
 
Solange dos Santos Moragas Barbosa 1 , Antônio Augusto de Freitas Peregrino 2 , Ana Clara de Melo 
Souza Tolentino 3, Daniel Aragão Machado 4, Vivian Schutz 5 
 
 
 
Objective: Identifying what has been produced on cost analysis of allogeneic transplantation of 
hematopoietic stem cell. Method: It consists of an integrative review, where was done a search of studies 
on cost analysis in allogeneic transplantation. Results: There were found 265 articles, which, after 
application of inclusion and exclusion criteria, 13 articles, with twelve in English and two in Portuguese 
were selected. Eleven of these articles have made partial cost analysis, a study done systematic review of 
cost-effectiveness; one made economic evaluation of cost-effectiveness and cost evaluation study made 
about coverage for curative catheter in transplantation. Conclusion: There is a gap in the area of 
economic evaluation studies and the nurse should occupy this space, not only as a care manager, but also 
of cost. Descriptors: Cost analysis, Allogeneic stem cell transplantation bone marrow. 
 
 
 
Objetivo: Identificar o que se tem sido produzido sobre análise de custos do transplante alogênico de 
células tronco hematopoiéticas. Método: Consta de uma revisão integrativa, em que se fez a busca de 
estudos sobre análise de custos em transplante alogênico. Resultados: Foram encontrados 265 artigos dos 
quais após aplicação dos fatores de inclusão e exclusão foram selecionados 13 artigos, sendo 12 de língua 
inglesa e dois de língua portuguesa. Onze desses artigos fizeram análise parcial de custos, um estudo fez 
revisão sistemática sobre custo-efetividade, um fez avaliação econômica de custo-efetividade e um estudo 
fez avaliação de custo sobre cobertura para curativo de cateter no transplante. Conclusão: Existe uma 
lacuna na área de estudos de avaliação econômica e o enfermeiro deveria ocupar este espaço como 
gerenciador não só do cuidado, mas também de custos. Descritores: Análise de custos, Transplante 
alogênico de medula óssea. 
 
 
 
Objetivo: Identificar lo que se ha producido en el análisis de costos de trasplante de las células madre 
hematopoyéticas alogénicas. Método: Se trata de una revisión integradora, donde hizo la búsqueda de los 
estudios sobre el análisis de costos en el trasplante alogénico. Resultados: Se encontraron 265 artículos 
que después de la aplicación de criterios de inclusión y exclusión 13 artículos, con doce en Inglés y dos en 
Portugués fueron seleccionados. Once de estos artículos han hecho análisis parcial de los costos, un 
estudio realizado una revisión sistemática de la rentabilidad, una evaluación económica hecha de costo-
efectividad y el estudio de evaluación de costos sobre la cobertura de catéter curativa en el trasplante. 
Conclusión: Existe un vacío en el área de estudios de evaluación económica y la enfermera debe ocupar 
este espacio, no sólo como gestora de la atención, sino también de costo. Descriptores: Análisis de costos, 
Trasplante alogénico de células madre de la médula. 
 
 
1Nurse, Master of Sciences Student at Alfredo Pinto School of Nursing/ Federal University of Rio de Janeiro State.  2Nurse, PhD, 
Professor at Rio de Janeiro State University. 3Nurse, Master of Sciences from Alfredo Pinto School of Nursing/ Federal 
University of Rio de Janeiro State. 4Nurse, PhD, Professor at Alfredo Pinto School of Nursing/ Federal University of Rio de 
Janeiro State.  5Nurse, PhD, Professor at Alfredo Pinto School of Nursing/ Federal University of Rio de Janeiro State. 
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ransplantation of Hematopoietic Stem (HSCT) remains the only 
alternative cells with the potential to cure for several hematologic malignancies. 1 
Technological advances in HSCT increased costs related to treatment in recent decades. 
Today, it is considered limited the knowledge about the economic aspects in HSCT, as well 
as its economic impact on our health care system. 1 
The HSCT is classified in the Unified Health System (SUS), as a procedure of high 
complexity and funding considered strategic by the health ministry, through the Fund for 
Strategic Actions and Settlements FAEC.2 
From the administrative point of view, it is an activity that requires materials, medical 
and nursing staff, the areas of diagnosis and treatment resources. From a technical 
standpoint, it is a procedure that due to its high complexity; patients are at higher risk and 
require a greater number of nursing hours due to the need for care and long-term.3 
The HSCT is a procedure consisting of three phases, the first phase corresponds to the 
period from pre-transplant evaluation until the end of chemotherapy conditioning, the 
second phase corresponds to the single-day infusion of new cord, and includes the collection 
of stem cells, and the third stage is the post-transplant to 100 days.4 
At the stage of post-transplantation there is a higher incidence of morbidity. In this 
period the demand is for more professionals, especially the nursing staff, due to variations 
in the degree of dependence, because a patient who now serves the requests and verbally 
expresses how he feels can suddenly evolve into a state of coma and multiple organ failure 
during this period. Complications from the procedure (HSCT) are variable and directly 
proportional to the increase in direct costs of treatment severities itself, because the higher 
the gravity, the greater use of technology, supplies and medications and hours worked 
multidisciplinary team.5 
Epidemiological data show that in 2013, until the month of March, 356 transplants were 
performed with the participation of 30 teams across Brazil with 206 autologous and 150 
allogeneic.6  Cost estimates for bone marrow transplantation are found in the scientific 
literature, referring mainly to other countries.7 A European study states that the cost 
difference between autologous and allogeneic HSCT is significant, with an estimated U$ 
25.564 for allogeneic and $18.000 for autologous (R). In a report of the Court of Audit 
(TCU), published in 2006, found reports of total spending transplants (all types) in the order 
of U.S. $ 185.685.222.00 for the year 2003. In a study published in the United States, 
spending HSCT per case are of the order of U$ 193.000,00.3    Whatever the impact of HSCT 
in the coffers of the NHS, it is certainly a macroeconomic character, ie, impacts the health 
system in all regions. Adverse effects associated with the intervention should be included 
and valued when they are clinically and economically important and or based on significant 
differences between the intervention and its alternatives studied.7 
INTRODUCTION 
ISSN 2175-5361                                                DOI: 10.9789/2175-5361.2014.v6i4.1642-1654                     
Barbosa SSM, Peregrino AAF, Tolentino ACMS et al.                           Cost of hematopoietic… 
 
 
J. res.: fundam. care. online 2014. out./dez. 6(4):1642-1654 1644 
 
The adverse effects that lead patients to serious health conditions and hence to greater 
economic expenditure on care of it, should have special attention, with regard to clinical 
and economic research.7 
 Clinical researches addressing the costs of HSCT are difficult to be conducted, due to 
the large variation in the protocols used in distinct clinical and support care situations.8 In 
recent multicenter European study, published in the year 2012, the total average costs of 
allogeneic HSCT including selection and collection Hematopoietic stem cells (HSC) 
transplantation and follow-up of 1 year ranged from U$ 76.624,00 to U$ 191.496,00.9 
The immune vulnerability becomes transplant patients susceptible to a variety of 
opportunistic infections due to their immune dysfunctions complex system, a condition 
more critical with the use of certain immunosuppressive treatment. Studies show that 
infections are a major cause of increased costs with transplantation, including those related 
to disease Graft- versus-host disease (GVHD).2,3,7-9 There are few studies in Brazil about the 
activity of specific nursing relating it as a contribution towards improving the science of 
care, ie, the quality of care associated with the rational use of resources and reducing 
expenditures primarily with regard to the assistance of nursing HSCT.  
The ability to apply critical thinking and clinical decision making, as well as consulting 
and collaboration with the multidisciplinary team, contribute to better meet patient 
demand for acute care.10 The professional nurse is present in all services and work close to 
customers has great potential to evaluate and ensure efficient assistance. Nurses who 
administer health services should be trained with the topic of costs, primarily related to 
assistance to hospitalized patients.11 
Therefore, become important studies that address the economic issue, and the economic 
health evaluation, the most suitable as they allow mapping problems and the impacts of the 
use of technology in the healthcare system.11 
The economic evaluation is a formal technique for comparing alternative proposals for 
action, both in terms of its costs, as the consequences, positive or negative12 and help 
managers in the choice of the best alternative. The financing of the health system is a 
challenge because it is faced with budget constraints facing a growing demand for 
resources, which leads to an impasse manager in decision making. There are studies of 
economic evaluation: cost-minimization, cost-effectiveness, cost-benefit and cost-utility. If 
a study is done only lifting costs then constitutes a partial cost-analysis.13 
This study aims to make an integrative literature review on cost analysis of allogeneic 
HSCT, identifying what has been produced on this topic over the past 10 years, according to 
the following guiding questions: What is the cost of allogeneic HSCT? Are there studies in 
nursing to address the issue of costs in allogeneic HSCT? 
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METHOD 
 
 
 
 
 
 
It was developed an integrative review, where was done the search for studies on cost 
analysis in HSCT. Searches of data were conducted in Medline, LILACS, EMBASE, IBECS, in 
the months of July and August 2013. For the literature review, we used the PICO anagram, 
which guides us to formulate a research question and do a search of adequate descriptors. 
This procedure is a characteristic of evidence-based practice: 
P  Paciente Paciente transplantado de medula óssea 
I  Intervenção Transplante alogênico 
C  Comparador Não há 
O  Outcomes (desfechos) Custos 
     Figure 1: PICO Anagram 
The next phase in the pursuit of descriptors for each element of the anagram for each 
database: 
Descritores p/ paciente transplantado de medula óssea  
Bone marrow transplant patients or in-patients 
Descritores p/ transplante alogênico 
 Allogeneic bone marrow transplantation  or  Allogeneic hematopoietic stem cell transplant 
Descritores p/ custo 
Costs and cost analysis or increased costs or costs or cost control or cost allocation or fees and charges 
Figure 2: Search at Medline. 
 
Descritores p/ paciente transplantado de medula óssea 
Paciente transplantado de medula óssea or pacientes sometidos a transplante de medula óssea or paciente 
transplantado de células tronco Hematopoéticas or paciente internado or paciente hospitalizado 
Descritores p/ transplante alogênico 
Transplante alogênico de células tronco Hematopoéticas or transplante alogênico de células madre 
hematopoyéticas or transplante alogênico de medula ósea 
Descritores p/ custo 
Costos or custos e análise de custo or costos y análisis de costo or costos directos de serviços or asignación de 
costos 
Figure 3: Search at LILACS. 
 
The Embase uses the same descriptors as Medline does. The IBECS uses descriptors of 
Lilacs. The survey was taken, using the Boolean operators "AND" and "OR" for the association 
of descriptors. The inclusion criteria were applied: 1)articles published in the last 10 years 
(2003-2013), 2) English, Portuguese and Spanish; 3) Articles available in full. 4) cost-
approach. Exclusion criteria: 1) papers addressing pediatric transplantation. 2) items that 
only had abstracts, articles on 3) autologous transplantation. The selection process 
consisted of work: choices for titles and then choose by reading the abstracts. Analysis of 
the studies was done by thorough reading of selected articles. To organize and provide 
clarity in publications found a table was used consisting year of publication, database 
descriptors used, the methodology used in the study, authors and journal. 
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RESULTS AND DISCUSSION 
 
 
 
 
 
 
Were found 265 items after application of inclusion and exclusion criteria, 13 studies 
were selected: 12 English-language and two English language were found. Most of the 
articles found in Medline (13) data and found an article in lilacs. The year that showed the 
publications was 2012, with 31% of the total. According to the definition Economic 
Assessment, 11 articles did partial cost analysis in HSCT, a study done a systematic review 
of cost-effectiveness in Hematopoietic Stem Cell Transplantation, another study did cost-
effectiveness analysis of treatment of GVHD and study conducted by nurses did cost 
assessment on coverage for curative catheter. 
Nome do artigo Base de dados Author Ano Periódico Metodologia 
Economic cost of Peripheral 
Blood Progenitor Cell in Spain14 
Medline 
Sanches 
et al. 
2004 
Medicina cl 
De 
Barcelona 
Análise parcial 
de custos 
Economic analysis of unrelated 
BMT: results15 
Medline Lissovoy 2005 BMT 
Análise total 
Custo-
efetividade 
Costs of allogeneic 
hematopoietic stem cell 
transplantations16 
Medline Svahn 2006 
Transplantat
ion 
Análise parcial 
de custos 
Treatment costs and survival in 
with grades III-IV17 
Medline Svahn 2006 
Transplantat
ion 
Análise parcial 
de custos 
Lower costs associated with 
HCT using reduced intensity vs 
high dose regimens for 
malignancy18 
Medline Saito 2007 BMT 
Estudo de 
coorte 
Cost of allogeneic HCT with 
high dose regimens19 
Medline Saito 2008 
Biol  Blood 
marrow 
transplantati
on 
Análise parcial 
de custos 
Costs of hematologic cell 
transp. Comparison20 
Medline Majhail 2009 Ann hemat 
Análise parcial 
de custos 
Avaliação das coberturas para 
sítio de inserção de CVC no 
TMO21 
LILACS Andrade 2011 Reme 
Análise parcial 
de custos 
Preditores de mortalidade e 
custo em TCTH22 
Medline Kerbauy 2012 Einstein 
Análise parcial 
de custos 
Costs and cost-efectiveness of 
TCTH23 
Medline Preussler 2012 
Biol blood 
marrow 
transp 
Estudo de 
revisão 
High readmission rates are 
associated24 
Medline Digman 2012 
Clinical 
transp 
Análise parcial 
de custos 
Real–world costs of autol and 
allog25 
Medline 
Blommes
tein 
2012 Ann hemat 
Análise parcial 
de custos 
Increased costs after allog 
hematopoétic26 
Medline Svahn 2012 BMO 
Análise parcial 
de custos 
Table 1: Articles included. 
 
Descriptive presentation of the articles found 
Article 1 - Cost of Allogeneic HCT with High Dose Regimens; Author: Akiko Saito; Periódico: 
Biol Blood Marrow Transplantation; Ano: 2008.19 
Objectives: To characterize the costs of allogeneic transplantation with high-dose 
conditioning regimens, identify factors related to increased costs in transplantation. 
Methodology: An observational study in which 315 patients undergoing hematopoietic stem 
cell transplantation (HSCT) were analyzed over a period of four years, starting in 2000, 
through multivariate analysis of factors pre and post HSCT related to rising treatment costs. 
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Results: The average cost of hospitalizations and days of hospitalization were U $ 102,574 
and 36 days of hospitalization in the first 100 days and U $ 128,800 and 39 days of 
hospitalization within one year. The initial costs (those within the first 100 days) accounted 
for 84% of total costs in the first year. Hospitalization costs comprise 94% of the initial 
costs, but only 61% of subsequent costs defined as costs incurred between 101 days and the 
first year. Of post HSCT factors, serious complications that increased the total cost U $ 20 
228 were identified. These results provide cost estimates for complicated and 
uncomplicated procedures as well as the costs for managing specific complications of HSCT. 
 
Article 2: Title: Predictors of Mortality and Cost of Hematopoietic Stem Cell 
Transplantation. Author: Fábio Rodrigues Kerbauy et al; periódico: gestão e Economia em 
Saúde, ano 2012.22 
Objectives: To assess the association of risk score (PAM pre-transplantation assessment of 
mortality) with the cost of transplantation and use it as a cost management tool. 
Methodology: it was a retrospective study with a sample of 116 patients of allogeneic and 
autologous HSCT, being 27 in cohorts allogeneic and 89 in autologous cohorts, in the period 
from 2004 to 2006, at the Albert Einstein Hospital in Sao Paulo. 
Results: (Risk score PAM can be classified into four categories according to the probability 
of death during the first two years after transplantation: Category 1 less than 25%; 
category2: 25% to 50%; Category3: 50 % to 75% and grade 4, greater than 75%). According to 
the risk score PAM it was possible to classify all patients into three risk categories (high, 
intermediate and low). The average cost in U.S. dollars for the high, intermediate and low 
risk groups were respectively U$ 281,000, U$ 73,000 and U$ 54,400. The cost of HSCT was 
significantly different for each PAM risk group (P = 0.008). 
 
Article 3: Costs of allogeneic hematopoietic stem cell transplantation. Autor: B.L. Svahn; 
ano: 2006; periódico: Transplantation.16 
Objectives: determining the total cost of treatment after allogeneic HSCT; identify factors 
associated with increased or reduced costs. 
Methodology: the costs of 93 patients who underwent allogeneic HSCT between 1998 and 
1999 were collected in the five years after the procedure. In the first stage of the study 
costs the costs of readmission and outpatient follow-up were analyzed from the first day of 
admission until discharge and then. 
Results: The average total cost of five years after HSCT was 139.414 euros. Costs were 
higher during the first hospitalization (EUR 100.650) and outpatient costs were around 
13,066 euros. The total cost for the first year was higher in patients with chronic graft 
grade II to IV, followed by bacteremia, VOD (veno-occlusive disease of the liver), 
prophylaxis with GCS-F and patients with acute leukemia. The higher costs are associated 
with re-transplantation, LMA, prophylaxis with GCSF, hospital care, myeloablative 
conditioning and major complications of transplantation. 
 
Article 4: Costs and Cost-Effectiveness of Hematopoietic Cell Transplantation; autor: Jaime 
Preussler et al; ano: 2012; periódico: ASBMT.23 
Objectives: Make a survey of studies on costs and cost-effectiveness HSCT 
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Methodology: A survey of articles published from January 2000 to July 2011 was conducted. 
The descriptors were economic cost analysis, analysis, economic evaluation, cost-
minimization, cost- benefit, cost-utility and cost; descriptors for transplants were 
allogeneic bone marrow transplantation, autologous bone marrow transplantation, bone 
marrow transplantation related, Hematopoietic stem cell transplantation (HSCT), and 
Hematopoietic stem cell transplantation of peripheral blood. A manual search of 
bibliographies of relevant original studies describing economic evaluation of diseases 
treatable with HSCT, with the exception of breast cancer was made. There were 205 
abstracts, which after screening identified 30 articles, of which 10 were excluded for not 
describing costs and be narrative review, remaining 20 articles to be included in this 
review. 
Results: According to the survey, in the U.S., costs for allogeneic transplantation, ranging 
from U$ 80.499 to U$ 137.564 were identified, according to donor and intensity of the 
conditioning regimen. An average of U$ 51.312 for autologous transplantation was found. 
Some increased costs associated with the transplant as treatment for complications and 
transplant the patient with advanced disease factors were identified. Hospitalization was 
the main contributor to increased costs in the first 100 days. The economic impact of long-
term care and chronic graft versus host chronic (cGVHD) is unclear. Studies found six 
examined the cost-effectiveness, but the available findings are not consistent due to 
variations in the comparison of treatment methods between studies. 
 
Article 5: Economic Cost of peripheral blood progenitor Cell in Spain. Autor: Sanchez et al; 
ano 2004; periódico:  medicina Clínica Barcelona.14 
Objectives: To analyze the economic impact of allogeneic HSCT in the health system 
Methodology: the costs of the 67 transplant patients were analyzed, 48 autologous and 
allogeneic 19, in a period of two years. 
Results: The collection of stem cells for autologous HSCT was significantly more expensive 
compared to allogeneic HSCT. Research expenditures in allogeneic donor evaluation context 
became more expensive pre transplant. The transplant itself is more expensive in 
allogeneic, which is explained by longer hospitalization. Total expenditure on autologous 
HSCT was 24.000 euros and allogeneic HSCT around 34.000 euros. 
 
Article 6: Lower costs associated with hematopoietic cell transplantation using reduced 
intensity vs high dose regimens for hematological malignancy. Autor: Akiko Saito et al, 2007 
Periódico: Bone MarrowTransplantation.18 
Objectives: The aim of this study costs HSCT among patients receiving reduced-intensity 
conditioning with those who received conditioning regimen in high-dose regimens was 
compared. 
Methodology: The study population included 457 patients who underwent HSCT from June 
2000 to September 2003. 10 patients who had been transplanted for less than a year and 
172 patients who received depleted graft, graft incompatible graft cord and carriers of 
hereditary diseases were excluded in order to improve comparability between the two 
procedures. The study was an observational cohort where the disease state, severity of 
condition, the cell source and prophylaxis of GVHD were classified. 
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Results: The total costs of the system of reduced intensity vs. high-dose regimen in 275 
patients were compared over 3 years. The procedures for HSCT with reduced intensity 
regimen cost U$ 53.000 less and about 16 fewer days of hospitalization. However, long term 
clinical results were similar to the other group in accordance with the literature. Although 
it seems intuitive that early discharge of patients reduce costs, this strategy will only work 
if reductions are made in the intensity of the conditioning regimen, in order to enable the 
outpatient HSCT and no increase in relapse rates or other late complications that may 
increase costs and the need for hospitalizations in later periods. 
 
Article 7: High readmission rates are associated with a significant economic burden and 
poor outcome in patients with grade III/IV acute GvHD. Autor: Digman F. L. et al; ano: 2012; 
periódico: Clinical Transplantation.24 
Objectives: To assess the impact of GVHD in readmission rates and hospital costs. 
Methodology: Retrospective analysis of readmission rates and associated costs in 187 
patients undergoing allogeneic HSCT to assess the economic impact of GVHD. The study 
period was from 2006 to 2009. 
Results: The average cost of re-hospitalization was higher in patients with GVHD (EUR 
128.860) than in patients without GVHD (13.405 euros). The cost of treatment was 
significantly higher in patients with GVHD grade III and IV (40.012 euros) compared with 
patients with grade I and II (24.560). The average cost of re-hospitalization for relapse was 
higher in the group without GVHD (2.202 euros) compared with the group with GVHD 
(1.222). 
 
Article 8: Real –World Costs of Autologous and Allogeneic Stem Cell transplantations for 
Haematological diseases: A Multicentre Study. Autor: Blommestein, HM et al; Ano: 2012; 
Periódico: Ann Hematol.25 
Objectives: To estimate the costs of autologous and allogeneic HSCT for hematologic 
diseases; Identify key cost factors; Compare the real cost of the procedure with the value 
that is reimbursed. 
Methodology: A retrospective study whose population was patients undergoing HSCT for 
hematological diseases in the years 2007-2009. The selection was random, in three Dutch 
university hospitals, whose number was 191 patients. Phases of HSCT (phase 1 selection and 
collection) were categorized (phase 2 hospitalization), (3 phase high post). 
Results: The average cost was found to autologous (45.668 euros). The stage was more 
expensive transplant hospitalization, cost of 21.124 euros. The average cost for allogeneic 
Akin was 101.923 euros, and the phase of the least expensive procedure, comparing with 
the phase of testing and gathering. It was observed that the costs of HSCT with unrelated 
donor were much higher with an average of 171.482 euros. The average and median costs 
for HSCT cord were 254.690 and 167.289 euros respectively. This study led to an increase 
reimbursement rates. 
 
Article 9: Costs of hematopoietic cell Transplantation: Comparison of umbilical Cord Blood 
and matched related Donor transplantation and the Impact of Posttransplant Complications; 
autor: Majhail, NS et al; ano 2009; periódico: Biol Blood Marrow transplant.20 
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Objectives: assessing the costs of HSCT cord with myeloablative and non-myeloablative 
conditioning regimens. Compare HSCT cord with both regimens with bone marrow HSCT; 
identify factors associated with increased costs. 
Methodology: This was a retrospective cohort study in a group of patients receiving HSCT 
adults between 2004 and 2006. A total of 318 eligible patients, 24 were excluded because 
they were autologous and mini-allo for Multiple Myeloma. The final study cohort consisted 
of 294 subjects. 
Results: The total cost for HSCT cord was U$ 137.564 compared to U$ 83,583 for combined 
HSCT (matched). Patients undergoing myeloablative non-myeloablative HSCT and umbilical 
cord were more prolonged hospitalization, and consequently higher costs. The main factors 
related to increased costs were: graft failure, dialysis, mechanical ventilation, and 
prolonged hospitalization. 
 
Article 10: Treatment costs and Survival in patients with grades III- V acute graft-versus-
host disease after allogeneic stem celltransplantation during three decades autor: B.M. 
Svahn; ano 2006; periódico: transplantation.17 
Objectives: to survey costs of treating acute GvHD grade III and IV; Calculating the survival 
of patients with acute GVHD grade III and IV. 
Methodology: A retrospective study with a sample of 88 patients was divided into three 
groups: 
Group A: HSCT between 1977-1989 
Group B: HSCT between 1990-1999 
Group C: HSCT between 2000-2004 
Treatment costs and survival rates were calculated. 
Results: increased survival rate of 1 year for the group C of 21% compared with 9% and 8% 
for groups A and B respectively was observed. Death by Acute GVHD was higher in the re-
transplantation. Grade IV acute GVHD was associated with increased cost of treatment. It 
was concluded that the costs and survival rates associated with acute GVHD have increased 
in recent years. 
 
Article 11: Increased costs after allogeneic hematopoietic complications and re-
transplantation; autor: B. M. Svahn et al; ano 2012; periódico: Bone Marrow 
transplantation.26 
Objectives: To evaluate factors associated with the high cost of transplanting; Compare 
different conditioning regimens (myeloablative, reduced intensity and non-myeloablative). 
Methodology: A retrospective study in a single university hospital. 202 patients undergoing 
allogeneic HSCT were included. 
Results: The average cost of transplantation in the initial treatment period was 66,756 
euros. The average cost for the first year of treatment was 141.493 euros. An increase in 
costs compared to cord blood transplantation. There were no significant differences 
between the regimes of reduced intensity and non-myeloablative. 
 
Article 12: Economic Analysis of Unrelated Bone Marrow transplantation: results from the 
randomized Clinical trial T-Cell depletion vs Unmanipulated grafts for the Prevention of 
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Graft-versus-lost diseases economic analysis. Autor: Lissovoy ET AL; ano2005; periódico: 
Bone Marrow Transplantation.15 
Objectives: To analyze the disease-free survival for three years in patients who received 
unrelated grafts with T cell depletion; compare these patients with those who received 
unrelated grafts without T cell depletion Analyzing the costs of treatment for GVHD in both 
groups. This was a study of cost effectiveness. 
Methodology: All patients eligible for unrelated HSCT were selected for the study. The first 
patient was enrolled in March 1995 and the last was in October 2000. It was a cohort study, 
multicenter (9 centers). Altogether 396 patients were recruited, 194 which received marrow 
T-cell depletion and cyclosporine protocol, and 204 received bone marrow without 
manipulation protocol with MTX and cyclosporine. Cost- effectiveness was taken. 
Results: The cost of treatment can be associated with longer survival, which incurs higher 
costs. The costs for the two treatment subgroups were similar within the category survival 
time. Patients receiving marrow cells were less prone to depletion severe cases of GvHD. In 
the first 100 days after HSCT 64,8% of patients with GVHD degrees of depletion had near 
zero, while 41.4% of the group experienced no depletion acute GVHD grade III-IV. The 
average costs increased progressively as the severity of GVHD. Regarding cost-effectiveness, 
there was no difference in survival at three years, and no difference in benefits for both 
groups. 
 
Article 13: Avaliação das coberturas para sítio de inserção do cateter venoso central no 
TMO: Análise de custos; autor: Andrade, AM et al; ano 2011,periódico: REME.21 
Objectives: To analyze the utilization and cost of different types of roofing CVC in relation 
to the frequency of exchange and frequency of device-related infections. 
Methodology: Data were collected from 68 patients undergoing autologous BMT in UFJF 
university hospital, from January 2006 to October 2009. Data regarding the technique of 
dressing covering used (sterile gauze or movie), frequency of replacement and costs derived 
from these procedures were analyzed. 
Results: The most repeated toppings were the polyurethane film with 51% usage and 21% 
with gauze. The cost generated by each use of the film was R$ 17,74 and the cost generated 
by each Sterile gauze was R$ 7,12. As the latter must be changed every 24 hours, your 
weekly cost was R$ 49,84. The permanence of the film is 4 to 7 days in 80% of cases. 
According to Silva, one of the advantages of the polyurethane film is the possible reduction 
of vascular infection beyond the direct visualization of the insertion site without removing 
the bandage that provides comfort and well-being of the patient. The change intervals 
transparent dressing is larger than those with gauze, thus reducing the inputs necessary for 
its realization, nursing time and consequently the hospital cost. 
Economic assessment studies are still scarce in health, even in oncology, and the 
various treatments are costly. Studies have methodological quality were the most 
backward, and show that much remains to be done to the level of research in the area of 
costs. 
In studies of transplantation in cost due to the many variables encountered types of 
transplant treatment protocols, different size samples. All this makes it difficult 
comparative studies in bone marrow transplantation. If teams develop the full Economic 
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